| Recruiting | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | 2023-08-28 |
| Terminated | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Advanced Solid Tumors | Phase 1 | 2022-07-13 |
| Withdrawn | Long-term Registry of Patients Treated With Loncastuximab Tesirine B-Cell Lymphomas | — | 2022-06-30 |
| Terminated | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants Wit Diffuse Large B-cell Lymphoma | Phase 2 | 2022-06-21 |
| Recruiting | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other An B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 | 2022-06-17 |
| Withdrawn | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesiri Diffuse Large B-Cell Lymphoma | Phase 1 | 2022-02-01 |
| Terminated | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Rel Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | 2021-11-04 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Particip Advanced Solid Tumors | Phase 1 | 2021-09-09 |
| Active Not Recruiting | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapse Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | 2020-09-16 |
| Completed | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Ref Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | 2019-09-13 |
| Terminated | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle C Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma | Phase 1 | 2019-02-04 |
| Terminated | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2018-12-21 |
| Terminated | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphom Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | Phase 1 / Phase 2 | 2018-12-01 |
| Terminated | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer | Phase 1 | 2018-11-09 |
| Completed | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Di Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | Phase 2 | 2018-08-01 |
| Terminated | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) E Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer | Phase 1 | 2017-05-18 |
| Completed | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | 2016-03-01 |
| Terminated | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Acute Lymphoblastic Leukemia | Phase 1 | 2016-03-01 |
| Terminated | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-posi Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | 2016-02-01 |
| Completed | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Hodgkin Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | 2015-10-05 |
| No Longer Available | Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | — | — |